BDBM312172 Alternative Preparation::US10016430, Example 3::US11000525, Example 3::US9616063, 3

SMILES C[C@@H](N)c1cc(Cl)ccc1Cn1c2cc[nH]c2c(=O)[nH]c1=S

InChI Key InChIKey=BHKKSKOHRFHHIN-UHFFFAOYSA-N

Data  16 IC50  1 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 312172   

TargetCytochrome P450 2C9(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant CYP2C9 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 6.00E+3nMAssay Description:Competitive inhibition of human recombinant CYP3A4 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCytochrome P450 2C19(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant CYP2C19 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCytochrome P450 1A2(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant CYP1A2 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin) using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 2.10E+4nMAssay Description:Inhibition of hERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataKd:  501nMAssay Description:Displacement of benzhydroxamic acid from native state MPO (unknown origin) by 1D NMR reporter assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetThyroid peroxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 890nMAssay Description:Inhibition of human recombinant TPO (1 to 839 residues) expressed in baculovirus-infected insect cells measured after 15 mins in presence of H2O2 by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 800nMAssay Description:Inhibition of MPO in human HL-60 cells measured after 15 mins in presence of H2O2 by chemiluminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 7nMAssay Description:The pharmacological activity of compounds disclosed herein was tested in the following screen (Test A) in which the compounds were tested in the pres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/7/2019
Entry Details
Go to US Patent

TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetThyroid peroxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 4.30E+3nMAssay Description:Methods for the determination of MPO inhibitory activity are disclosed in WO 02/090575. The pharmacological activity of compounds disclosed herein wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 7nMAssay Description:Methods for the determination of MPO inhibitory activity are disclosed in WO 02/090575. The pharmacological activity of compounds disclosed herein wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
Go to US Patent

TargetThyroid peroxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 4.30E+3nMAssay Description:MPO: The pharmacological activity of compounds disclosed herein was tested in the following screen (Test A) in which the compounds were tested in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetMyeloperoxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 7nMAssay Description:MPO: The pharmacological activity of compounds disclosed herein was tested in the following screen (Test A) in which the compounds were tested in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetThyroid peroxidase(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM312172(Alternative Preparation | US9616063, 3 | US1001643...)
Affinity DataIC50: 4.30E+3nMAssay Description:To detect thyroid peroxidase (TPO) inhibitory activity, the production of hypoiodous acid (HOI) was quantified. HOI was detected by reacting it with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/7/2019
Entry Details
Go to US Patent